Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard E. Pratley, Aslam Amod, Søren T. Hoff, et al.
The Lancet (2019) Vol. 394, Iss. 10192, pp. 39-50
Closed Access | Times Cited: 445

Showing 1-25 of 445 citing articles:

Therapeutic peptides: current applications and future directions
Lei Wang, Nanxi Wang, Wenping Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 1155
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

Diabetes Care (2020) Vol. 44, Iss. Supplement_1, pp. S111-S124
Open Access | Times Cited: 890
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

Diabetes Care (2019) Vol. 43, Iss. Supplement_1, pp. S98-S110
Open Access | Times Cited: 865
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S140-S157
Open Access | Times Cited: 663
Type II diabetes mellitus: a review on recent drug based therapeutics
Santwana Padhi, Amit Kumar Nayak, Anindita Behera
Biomedicine & Pharmacotherapy (2020) Vol. 131, pp. 110708-110708
Open Access | Times Cited: 511
Advances in oral peptide therapeutics
Daniel J. Drucker
Nature Reviews Drug Discovery (2019) Vol. 19, Iss. 4, pp. 277-289
Closed Access | Times Cited: 495
G protein-coupled receptors: structure- and function-based drug discovery
Dehua Yang, Qingtong Zhou, Viktorija Labroska, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 425
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Materials for oral delivery of proteins and peptides
Tyler Brown, Kathryn A. Whitehead, Samir Mitragotri
Nature Reviews Materials (2019) Vol. 5, Iss. 2, pp. 127-148
Closed Access | Times Cited: 382
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S125-S143
Closed Access | Times Cited: 337
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani, et al.
Diabetes Care (2019) Vol. 42, Iss. 12, pp. 2272-2281
Open Access | Times Cited: 327
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 315
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S158-S178
Open Access | Times Cited: 314
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging
Arnold C.T. Ng, Victoria Delgado, Barry A. Borlaug, et al.
Nature Reviews Cardiology (2020) Vol. 18, Iss. 4, pp. 291-304
Closed Access | Times Cited: 248
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial
Bernard Zinman, Vanita R. Aroda, John B. Buse, et al.
Diabetes Care (2019) Vol. 42, Iss. 12, pp. 2262-2271
Open Access | Times Cited: 203
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 203
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Michael A. Nauck, Juris J. Meier
European Journal of Endocrinology (2019) Vol. 181, Iss. 6, pp. R211-R234
Open Access | Times Cited: 199
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
David J. Brayden, Timothy A. Hill, David P. Fairlie, et al.
Advanced Drug Delivery Reviews (2020) Vol. 157, pp. 2-36
Open Access | Times Cited: 198
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
Donna H. Ryan, Ildiko Lingvay, Helen M. Colhoun, et al.
American Heart Journal (2020) Vol. 229, pp. 61-69
Open Access | Times Cited: 197
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Jennifer M. Trujillo, Wesley Nuffer, Brooke A. Smith
Therapeutic Advances in Endocrinology and Metabolism (2021) Vol. 12
Open Access | Times Cited: 184
Safety of Semaglutide
Mark M. Smits, Daniël H. van Raalte
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 177
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 166
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 5, pp. 377-391
Open Access | Times Cited: 162
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
Mansoor Husain, Stephen C. Bain, Ole K. Jeppesen, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 3, pp. 442-451
Open Access | Times Cited: 152
Page 1 - Next Page

Scroll to top